Dabigatran elimination: Is haemodialysis effective?

Thrombosis and Haemostasis

Volumn 109, Issue 4, 2013, Pages 580-581

  McLellan, Alex J A ^a   Schlaich, Markus P ^a  

^a ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED CARBON; BLOOD CLOTTING FACTOR; DABIGATRAN; PROTHROMBIN COMPLEX; RECOMBINANT ACTIVATED FACTOR 7; UNCLASSIFIED DRUG; WARFARIN;

BLEEDING; CEREBROVASCULAR ACCIDENT; DRUG ELIMINATION; DRUG OVERDOSE; EDITORIAL; HEART ATRIUM FIBRILLATION; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PLASMAPHERESIS; PRIORITY JOURNAL; RISK;

ANTITHROMBINS; BENZIMIDAZOLES; BETA-ALANINE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; RENAL DIALYSIS;

EID: 84875940521     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-01-0064     Document Type: Editorial

References (15)

1. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
2. Ogilvie IM, Newton N, Welner SA, et al. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 2010; 123: 638-645 e4.
3. Wan Y, Heneghan C, Perera R, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes 2008; 1: 84-91.
4. Huisman MV, Lip GY, Diener HC, et al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 2012; 107: 838-847.
5. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
6. Pengo V, Crippa L, Falanga A, et al.; Italian Federation of Thrombosis Centers. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost 2011; 106: 868-876.
7. Marlu R, Hodaj E, Paris A, et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012; 108: 217-224.
8. Woo JS, Kapadia N, Phanco SE, et al. Positive Outcome After Intentional Overdose of Dabigatran. J Med Toxicol 2012; in press.
9. Kamboj J, Kottalgi M, Cirra VR, et al. Direct thrombin inhibitors: a case indicating benefit from 'plasmapheresis' in toxicity: a call for establishing "guidelines" in overdose and to find an "antidote"! Am J Ther 2012; 19: e182-185.
10. Stangier J, Rathgen K, Stahle H, et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010; 49: 259-268.
11. Chang DN, Dager WE, Chin AI. Removal of Dabigatran by Hemodialysis. Am J Kidney Dis 2012; in press.
12. Wanek MR, Horn ET, Elapavaluru S, et al. Safe use of hemodialysis for dabigatran removal before cardiac surgery. Ann Pharmacother 2012; 46: e21.
13. Warkentin TE, Margetts P, Connolly SJ, et al. Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood 2012; 119: 2172-2174.
14. Khadzhynov D, Wagner F, Formella S, et al. Effective elimination of dabigatran by hemodialysis: a phase I single centre study in patients with end stage renal disease. Thromb Haemost 2013; 109: 596-605.
15. Blech S, Ebner T, Ludwig-Schwellinger E, et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008; 36: 386-399.